ADPT — Adaptive Biotechnologies Corporation USA
[[ lastPrice | number : 2]]
[[ refundPrice | number : 2]]
[[ refundPriceP | number : 2]]%
[[ refundPriceP | number : 2]]%
[[ lastDate * 1000 | date:'MMM d, y @h:mm a' ]]
Currency in USD
Currency in USD
UB Rating 2.7/5 Hold
Basic
Not enough data for Expected Return.
Not enough data for Risks (Volatility).
Not enough data for Beta calculations.
Market capital
$1.09B
Employees
858
Money
Not enough data for Earnings per share statistics.
Not enough data for Book Value calculations.
Wall Street price
$18.25
PE Ratio
—
Dividends
$0.00
Volume & Social
Short Ratio
3.86%
Daily Volume
1.56M
Volume
Average
Social Rate
Untracked
Social Volume
Untracked
Latest ADPT news
[[ item.source ]]
-
[[ item.pubDate | date:'MMM d, y @ h:mma' ]]
[[ item.description ]]
Invest ideas
6 ideas for sell
22.86%
Fundamental signal
Short Interest Ratio is higher than industry.
29.93%
Fundamental signal
Short Interest Ratio is higher than sector.
Invest Ideas — the best way to get insights based on both fundamental and technical data.
We analyze company's performance across sector and industry and generate investing ideas for you.
Want to track signal changes?
It's easy to monitor changes in signal with our
watchlist. Just add the stock to your watchlist
and get daily, weekly and monthly signal changes for the asset.
Most and less correlated stocks. All correllations are calculated for 1 year period.
Learn more
about correlations.
Similar (most correlated) stocks
Correlation
96.40%
UB Rating
Correlation
95.00%
UB Rating
Correlation
94.80%
UB Rating
Correlation
94.60%
UB Rating
Correlation
94.20%
UB Rating
Correlation
93.80%
UB Rating
Correlation
93.30%
UB Rating
Correlation
93.30%
UB Rating
Correlation
93.20%
UB Rating
Correlation
93.20%
UB Rating
Opposite (less correlated) stocks
Correlation
−92.40%
UB Rating
Correlation
−89.90%
UB Rating
Correlation
−89.60%
UB Rating
Correlation
−89.30%
UB Rating
Correlation
−89.20%
UB Rating
Correlation
−88.60%
UB Rating
Correlation
−88.30%
UB Rating
Correlation
−88.20%
UB Rating
Correlation
−88.20%
UB Rating
Correlation
−87.90%
UB Rating
| All numbers in thousands | [[fin.date | strtotimestamp | date: 'MMM d, yyyy']] |
| Revenue | |
| Total Revenue | [[fin.totalRevenue / 1000 | number : 0]] |
| Cost of Revenue | [[fin.costOfRevenue / 1000 | number : 0]] |
| Gross Profit | [[fin.grossProfit / 1000 | number : 0]] |
| Operating Expenses | |
| Research Development | [[fin.researchDevelopment / 1000 | number : 0]] |
| Selling General and Administrative | [[fin.sellingGeneralAdministrative / 1000 | number : 0]] |
| Non Recurring | [[fin.nonRecurring / 1000 | number : 0]] |
| Others | [[fin.otherOperatingExpenses / 1000 | number : 0]] |
| Total Operating Expenses | [[fin.totalOperatingExpenses / 1000 | number : 0]] |
| Operating Income or Loss | [[fin.operatingIncome / 1000 | number : 0]] |
| Income from Continuing Operations | |
| Total Other Income/Expenses Net | [[fin.totalOtherIncomeExpenseNet / 1000 | number : 0]] |
| Earnings Before Interest and Taxes | [[fin.ebit / 1000 | number : 0]] |
| Interest Expense | [[fin.interestExpense / 1000 | number : 0]] |
| Income Before Tax | [[fin.incomeBeforeTax / 1000 | number : 0]] |
| Income Tax Expense | [[fin.incomeTaxExpense / 1000 | number : 0]] |
| Minority Interest | [[fin.minorityInterest / 1000 | number : 0]] |
| Net Income From Continuing Ops | [[fin.netIncomeFromContinuingOps / 1000 | number : 0]] |
| Non-recurring Events | |
| Discontinued Operations | [[fin.discontinuedOperations / 1000 | number : 0]] |
| Extraordinary Items | [[fin.extraordinaryItems / 1000 | number : 0]] |
| Effect Of Accounting Changes | [[fin.effectOfAccountingCharges / 1000 | number : 0]] |
| Other Items | [[fin.otherItems / 1000 | number : 0]] |
| Net Income | |
| Net Income | [[fin.netIncome / 1000 | number : 0]] |
| Net Income Applicable To Common Shares | [[fin.netIncomeApplicableToCommonShares / 1000 | number : 0]] |
| All numbers in thousands | [[fin.date | strtotimestamp | date: 'MMM d, yyyy']] |
| Current Assets | |
| Cash And Cash Equivalents | [[fin.cash / 1000 | number : 0]] |
| Short Term Investments | [[fin.shortTermInvestments / 1000 | number : 0]] |
| Net Receivables | [[fin.netReceivables/ 1000 | number : 0]] |
| Inventory | [[fin.inventory/ 1000 | number : 0]] |
| Other Current Assets | [[fin.otherCurrentAssets/ 1000 | number : 0]] |
| Total Current Assets | [[fin.totalCurrentAssets / 1000 | number : 0]] |
| Long Term Investments | [[fin.longTermInvestments / 1000 | number : 0]] |
| Property Plant and Equipment | [[fin.propertyPlantEquipment / 1000 | number : 0]] |
| Goodwill | [[fin.goodWill / 1000 | number : 0]] |
| Intangible Assets | [[fin.intangibleAssets / 1000 | number : 0]] |
| Other Assets | [[fin.otherAssets / 1000 | number : 0]] |
| Total Assets | [[fin.totalAssets / 1000 | number : 0]] |
| Current Liabilities | |
| Accounts Payable | [[fin.accountsPayable / 1000 | number : 0]] |
| Short/Current Long Term Debt | [[fin.shortLongTermDebt / 1000 | number : 0]] |
| Other Current Liabilities | [[fin.otherCurrentLiab / 1000 | number : 0]] |
| Total Current Liabilities | [[fin.totalCurrentLiabilities / 1000 | number : 0]] |
| Long Term Debt | [[fin.longTermDebt / 1000 | number : 0]] |
| Other Liabilities | [[fin.otherLiab / 1000 | number : 0]] |
| Deferred Long Term Liability Charges | [[fin.deferredLongTermLiab / 1000 | number : 0]] |
| Total Liabilities | [[fin.totalLiab / 1000 | number : 0]] |
| Stockholders' Equity | |
| Common Stock | [[fin.commonStock / 1000 | number : 0]] |
| Retained Earnings | [[fin.retainedEarnings / 1000 | number : 0]] |
| Other Stockholder Equity | [[fin.otherStockholderEquity / 1000 | number : 0]] |
| Total Stockholder Equity | [[fin.totalStockholderEquity / 1000 | number : 0]] |
| Net Tangible Assets | [[fin.netTangibleAssets / 1000 | number : 0]] |
| All numbers in thousands | [[fin.date | strtotimestamp | date: 'MMM d, yyyy']] |
| Net Income | [[fin.netIncome/ 1000 | number : 0]] |
| Operating Activities, Cash Flows Provided By or Used In | |
| Depreciation | [[fin.depreciation / 1000 | number : 0]] |
| Adjustments To Net Income | [[fin.changeToNetincome / 1000 | number : 0]] |
| Changes In Accounts Receivables | [[fin.changeToAccountReceivables / 1000 | number : 0]] |
| Changes In Liabilities | [[fin.changeToLiabilities / 1000 | number : 0]] |
| Changes In Inventories | [[fin.changeToInventory / 1000 | number : 0]] |
| Changes In Other Operating Activities | [[fin.changeToOperatingActivities / 1000 | number : 0]] |
| Total Cash Flow From Operating Activities | [[fin.totalCashFromOperatingActivities / 1000 | number : 0]] |
| Investing Activities, Cash Flows Provided By or Used In | |
| Capital Expenditures | [[fin.capitalExpenditures / 1000 | number : 0]] |
| Investments | [[fin.investments / 1000 | number : 0]] |
| Other Cash flows from Investing Activities | [[fin.otherCashflowsFromInvestingActivities / 1000 | number : 0]] |
| Total Cash Flows From Investing Activities | [[fin.totalCashflowsFromInvestingActivities / 1000 | number : 0]] |
| Financing Activities, Cash Flows Provided By or Used In | |
| Dividends Paid | [[fin.dividendsPaid / 1000 | number : 0]] |
| Sale Purchase of Stock | [[fin.salePurchaseOfStock / 1000 | number : 0]] |
| Net Borrowings | [[fin.netBorrowings / 1000 | number : 0]] |
| Other Cash Flows from Financing Activities | [[fin.otherCashflowsFromFinancingActivities / 1000 | number : 0]] |
| Total Cash Flows From Financing Activities | [[fin.totalCashFromFinancingActivities / 1000 | number : 0]] |
| Change In Cash and Cash Equivalents | [[fin.changeInCash / 1000 | number : 0]] |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
| Avg | -0.43 | -1.69 | -1.61 |
| High | -0.39 | -1.57 | -1.22 |
| Low | -0.52 | -1.90 | -1.97 |
| Avg | 50.3M | 189M | 193M |
| High | 52.6M | 191M | 200M |
| Low | 48.5M | 185M | 175M |
| [[fin.date | strtotimestamp | date: 'MMM d,yyyy']] | |
| Earnings History | |
| Earnings Actual | [[fin.epsActual | number : 2]] |
| Earnings Estimate | [[fin.epsEstimate | number : 2]] |
| Difference | [[fin.epsDifference | number : 2]] |
| Surprise | [[fin.surprisePercent | number : 1]]% |
| Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) | |
| Earnings Estimate | ||||
| Number of Analysts | [[financials['etrend']['0q'].earningsEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1q'].earningsEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['0y'].earningsEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1y'].earningsEstimateNumberOfAnalysts | number : 0]] |
| Estimate Average | [[financials['etrend']['0q'].earningsEstimateAvg | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateAvg | number : 2]] | [[financials['etrend']['0y'].earningsEstimateAvg | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateAvg | number : 2]] |
| Estimate High | [[financials['etrend']['0q'].earningsEstimateHigh | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateHigh | number : 2]] | [[financials['etrend']['0y'].earningsEstimateHigh | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateHigh | number : 2]] |
| Estimate Low | [[financials['etrend']['0q'].earningsEstimateLow | number : 2]] | [[financials['etrend']['0q'].earningsEstimateLow | number : 2]] | [[financials['etrend']['0y'].earningsEstimateLow | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateLow | number : 2]] |
| Estimate Growth | [[financials['etrend']['0q'].earningsEstimateGrowth | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateGrowth | number : 2]] | [[financials['etrend']['0y'].earningsEstimateGrowth | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateGrowth | number : 2]] |
| Year Ago EPS | [[financials['etrend']['0q'].earningsEstimateYearAgoEps | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateYearAgoEps | number : 2]] | [[financials['etrend']['0y'].earningsEstimateYearAgoEps | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateYearAgoEps | number : 2]] |
| All numbers in thousands (except analysts) | Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) |
| Revenue Estimate | ||||
| Number of Analysts | [[financials['etrend']['0q'].revenueEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['0y'].revenueEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateNumberOfAnalysts | number : 0]] |
| Estimate Average | [[financials['etrend']['0q'].revenueEstimateAvg / 1000 | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateAvg / 1000 | number : 0]] | [[financials['etrend']['0y'].revenueEstimateAvg / 1000 | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateAvg / 1000 | number : 0]] |
| Estimate High | [[financials['etrend']['0q'].revenueEstimateHigh / 1000 | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateHigh / 1000 | number : 0]] | [[financials['etrend']['0y'].revenueEstimateHigh / 1000 | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateHigh / 1000 | number : 0]] |
| Estimate Low | [[financials['etrend']['0q'].revenueEstimateLow / 1000 | number : 0]] | [[financials['etrend']['0q'].revenueEstimateLow / 1000 | number : 0]] | [[financials['etrend']['0y'].revenueEstimateLow / 1000 | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateLow / 1000 | number : 0]] |
| Estimate Growth | [[financials['etrend']['0q'].revenueEstimateGrowth * 100 | number : 2]]% | [[financials['etrend']['+1q'].revenueEstimateGrowth * 100 | number : 2]]% | [[financials['etrend']['0y'].revenueEstimateGrowth * 100 | number : 2]]% | [[financials['etrend']['+1y'].revenueEstimateGrowth * 100| number : 2]]% |
| Year Ago EPS | [[financials['etrend']['0q'].revenueEstimateYearAgoEps | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateYearAgoEps | number : 0]] | [[financials['etrend']['0y'].revenueEstimateYearAgoEps | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateYearAgoEps | number : 0]] |
| Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) | |
| EPS Trend | ||||
| Current Estimate | [[financials['etrend']['0q'].epsTrendCurrent | number : 2]] | [[financials['etrend']['+1q'].epsTrendCurrent | number : 2]] | [[financials['etrend']['0y'].epsTrendCurrent | number : 2]] | [[financials['etrend']['+1y'].epsTrendCurrent | number : 2]] |
| 7 Days Ago | [[financials['etrend']['0q'].epsTrend7daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend7daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend7daysAgo| number : 2]] | [[financials['etrend']['+1y'].epsTrend7daysAgo | number : 2]] |
| 30 Days Ago | [[financials['etrend']['0q'].epsTrend30daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend30daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend30daysAgo | number : 2]] | [[financials['etrend']['+1y'].epsTrend30daysAgo | number : 2]] |
| 60 Days Ago | [[financials['etrend']['0q'].epsTrend60daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend60daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend60daysAgo | number : 2]] | [[financials['etrend']['+1y'].epsTrend60daysAgo | number : 2]] |
| 90 Days Ago | [[financials['etrend']['0q'].epsTrend90daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend90daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend90daysAgo | number : 2]] | [[financials['etrend']['+1y'].epsTrend90daysAgo | number : 2]] |
| Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) | |
| EPS Revisions | ||||
| Up Last 7 Days | [[financials['etrend']['0q'].epsRevisionsUpLast7days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsUpLast7days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsUpLast7days | number : 0]] | [[financials['etrend']['+1y'].epsRevisionsUpLast7days | number : 0]] |
| Up Last 30 Days | [[financials['etrend']['0q'].epsRevisionsUpLast30days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsUpLast30days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsUpLast30days| number : 0]] | [[financials['etrend']['+1y'].epsRevisionsUpLast30days | number : 0]] |
| Down Last 30 Days | [[financials['etrend']['0q'].epsRevisionsDownLast7days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsDownLast7days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsDownLast7days | number : 0]] | [[financials['etrend']['+1y'].epsRevisionsDownLast7days | number : 0]] |
| Down Last 90 Days | [[financials['etrend']['0q'].epsRevisionsDownLast30days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsDownLast30days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsDownLast30days | number : 0]] | [[financials['etrend']['+1y'].epsRevisionsDownLast30days | number : 0]] |